Introduction to measurable residual disease (MRD)

Описание: Minimal residual disease (MRD) has become an important biomarker in both research and clinical settings for several hematological malignancies, including acute myeloid leukemia (AML).

In AML, MRD is used for its value in prognostic, predictive, monitoring and efficacy-response assessments. Guidelines for MRD are rapidly evolving, along with the technologies used to measure it.

At OGT we have developed an NGS solution for the detection of ultra low-frequency AML MRD-associated biomarkers. Visit our website to learn more about our SureSeq Myeloid MRD NGS Panel: https://www.ogt.com/us/products/produ...